Stent-based gene therapy

Marc D Feldman, Bo Sun, Bryan J. Koci, Clarence C. Wu, James R. Kneller, Harvey S. Borovetz, Simon Watkins, Ahmed Nadeem, Lee E. Weiss, Michael L. Reed, A. J Conrad Smith, Warren D. Rosenblum

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Delivery of gene therapy to inhibit intimal hyperplasia has been proposed to prevent postangioplasty restenosis. We sought to apply gene therapy by using a stent-based technique. There are several hurdles that must be overcome before gene-stent therapy can be applied successfully in clinical trials. These include increasing the efficiency of gene delivery through atherosclerotic plaque; increasing intramural retention times; preventing the inflammatory reaction that stents coated with biodegradable polymers can elicit; overcoming the risk of systemic gene delivery; and accessing the adventitia via percutaneous approach. We evaluated a gene-stent delivery mechanism based on microporous metal microneedles developed with nanotechnology in an attempt to overcome some of these problems. A novel approach to the transfection of genes by microfabricated technology was evaluated in smooth muscle cells in culture. We demonstrated that microneedles can deliver gene therapy to smooth muscle cells in culture and can produce controlled penetration of the IEL and intima. We conclude that taller microneedles need to be developed to reach the media in diseased human arteries and that this technology has the potential to be incorporated in a stent to deliver gene therapy in atherosclerotic plaque.

Original languageEnglish (US)
Pages (from-to)47-68
Number of pages22
JournalJournal of Long-Term Effects of Medical Implants
Volume10
Issue number1-2
StatePublished - 2000

Fingerprint

Gene therapy
Stents
Genetic Therapy
Genes
Atherosclerotic Plaques
Cell culture
Smooth Muscle Myocytes
Muscle
Cell Culture Techniques
Cells
Tunica Intima
Technology
Adventitia
Biodegradable polymers
Nanotechnology
Hyperplasia
Transfection
Polymers
Arteries
Metals

Keywords

  • Cells
  • Genes
  • Plaque
  • Restenosis
  • Smooth muscle cells

ASJC Scopus subject areas

  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Orthopedics and Sports Medicine
  • Pathology and Forensic Medicine

Cite this

Feldman, M. D., Sun, B., Koci, B. J., Wu, C. C., Kneller, J. R., Borovetz, H. S., ... Rosenblum, W. D. (2000). Stent-based gene therapy. Journal of Long-Term Effects of Medical Implants, 10(1-2), 47-68.

Stent-based gene therapy. / Feldman, Marc D; Sun, Bo; Koci, Bryan J.; Wu, Clarence C.; Kneller, James R.; Borovetz, Harvey S.; Watkins, Simon; Nadeem, Ahmed; Weiss, Lee E.; Reed, Michael L.; Smith, A. J Conrad; Rosenblum, Warren D.

In: Journal of Long-Term Effects of Medical Implants, Vol. 10, No. 1-2, 2000, p. 47-68.

Research output: Contribution to journalArticle

Feldman, MD, Sun, B, Koci, BJ, Wu, CC, Kneller, JR, Borovetz, HS, Watkins, S, Nadeem, A, Weiss, LE, Reed, ML, Smith, AJC & Rosenblum, WD 2000, 'Stent-based gene therapy', Journal of Long-Term Effects of Medical Implants, vol. 10, no. 1-2, pp. 47-68.
Feldman MD, Sun B, Koci BJ, Wu CC, Kneller JR, Borovetz HS et al. Stent-based gene therapy. Journal of Long-Term Effects of Medical Implants. 2000;10(1-2):47-68.
Feldman, Marc D ; Sun, Bo ; Koci, Bryan J. ; Wu, Clarence C. ; Kneller, James R. ; Borovetz, Harvey S. ; Watkins, Simon ; Nadeem, Ahmed ; Weiss, Lee E. ; Reed, Michael L. ; Smith, A. J Conrad ; Rosenblum, Warren D. / Stent-based gene therapy. In: Journal of Long-Term Effects of Medical Implants. 2000 ; Vol. 10, No. 1-2. pp. 47-68.
@article{c5be170f2007419683d4112ae50a2425,
title = "Stent-based gene therapy",
abstract = "Delivery of gene therapy to inhibit intimal hyperplasia has been proposed to prevent postangioplasty restenosis. We sought to apply gene therapy by using a stent-based technique. There are several hurdles that must be overcome before gene-stent therapy can be applied successfully in clinical trials. These include increasing the efficiency of gene delivery through atherosclerotic plaque; increasing intramural retention times; preventing the inflammatory reaction that stents coated with biodegradable polymers can elicit; overcoming the risk of systemic gene delivery; and accessing the adventitia via percutaneous approach. We evaluated a gene-stent delivery mechanism based on microporous metal microneedles developed with nanotechnology in an attempt to overcome some of these problems. A novel approach to the transfection of genes by microfabricated technology was evaluated in smooth muscle cells in culture. We demonstrated that microneedles can deliver gene therapy to smooth muscle cells in culture and can produce controlled penetration of the IEL and intima. We conclude that taller microneedles need to be developed to reach the media in diseased human arteries and that this technology has the potential to be incorporated in a stent to deliver gene therapy in atherosclerotic plaque.",
keywords = "Cells, Genes, Plaque, Restenosis, Smooth muscle cells",
author = "Feldman, {Marc D} and Bo Sun and Koci, {Bryan J.} and Wu, {Clarence C.} and Kneller, {James R.} and Borovetz, {Harvey S.} and Simon Watkins and Ahmed Nadeem and Weiss, {Lee E.} and Reed, {Michael L.} and Smith, {A. J Conrad} and Rosenblum, {Warren D.}",
year = "2000",
language = "English (US)",
volume = "10",
pages = "47--68",
journal = "Journal of Long-Term Effects of Medical Implants",
issn = "1050-6934",
publisher = "Begell House Inc.",
number = "1-2",

}

TY - JOUR

T1 - Stent-based gene therapy

AU - Feldman, Marc D

AU - Sun, Bo

AU - Koci, Bryan J.

AU - Wu, Clarence C.

AU - Kneller, James R.

AU - Borovetz, Harvey S.

AU - Watkins, Simon

AU - Nadeem, Ahmed

AU - Weiss, Lee E.

AU - Reed, Michael L.

AU - Smith, A. J Conrad

AU - Rosenblum, Warren D.

PY - 2000

Y1 - 2000

N2 - Delivery of gene therapy to inhibit intimal hyperplasia has been proposed to prevent postangioplasty restenosis. We sought to apply gene therapy by using a stent-based technique. There are several hurdles that must be overcome before gene-stent therapy can be applied successfully in clinical trials. These include increasing the efficiency of gene delivery through atherosclerotic plaque; increasing intramural retention times; preventing the inflammatory reaction that stents coated with biodegradable polymers can elicit; overcoming the risk of systemic gene delivery; and accessing the adventitia via percutaneous approach. We evaluated a gene-stent delivery mechanism based on microporous metal microneedles developed with nanotechnology in an attempt to overcome some of these problems. A novel approach to the transfection of genes by microfabricated technology was evaluated in smooth muscle cells in culture. We demonstrated that microneedles can deliver gene therapy to smooth muscle cells in culture and can produce controlled penetration of the IEL and intima. We conclude that taller microneedles need to be developed to reach the media in diseased human arteries and that this technology has the potential to be incorporated in a stent to deliver gene therapy in atherosclerotic plaque.

AB - Delivery of gene therapy to inhibit intimal hyperplasia has been proposed to prevent postangioplasty restenosis. We sought to apply gene therapy by using a stent-based technique. There are several hurdles that must be overcome before gene-stent therapy can be applied successfully in clinical trials. These include increasing the efficiency of gene delivery through atherosclerotic plaque; increasing intramural retention times; preventing the inflammatory reaction that stents coated with biodegradable polymers can elicit; overcoming the risk of systemic gene delivery; and accessing the adventitia via percutaneous approach. We evaluated a gene-stent delivery mechanism based on microporous metal microneedles developed with nanotechnology in an attempt to overcome some of these problems. A novel approach to the transfection of genes by microfabricated technology was evaluated in smooth muscle cells in culture. We demonstrated that microneedles can deliver gene therapy to smooth muscle cells in culture and can produce controlled penetration of the IEL and intima. We conclude that taller microneedles need to be developed to reach the media in diseased human arteries and that this technology has the potential to be incorporated in a stent to deliver gene therapy in atherosclerotic plaque.

KW - Cells

KW - Genes

KW - Plaque

KW - Restenosis

KW - Smooth muscle cells

UR - http://www.scopus.com/inward/record.url?scp=0034089579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034089579&partnerID=8YFLogxK

M3 - Article

C2 - 10947629

AN - SCOPUS:0034089579

VL - 10

SP - 47

EP - 68

JO - Journal of Long-Term Effects of Medical Implants

JF - Journal of Long-Term Effects of Medical Implants

SN - 1050-6934

IS - 1-2

ER -